First Light Asset Management LLC Acquires New Holdings in Disc Medicine, Inc. $IRON

First Light Asset Management LLC bought a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 231,186 shares of the company’s stock, valued at approximately $15,277,000. Disc Medicine accounts for 1.4% of First Light Asset Management LLC’s holdings, making the stock its 26th largest position. First Light Asset Management LLC owned 0.61% of Disc Medicine as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Aster Capital Management DIFC Ltd purchased a new position in shares of Disc Medicine in the 3rd quarter valued at $38,000. Avanza Fonder AB lifted its stake in shares of Disc Medicine by 54.0% during the 3rd quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after purchasing an additional 585 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in Disc Medicine by 8.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock valued at $133,000 after purchasing an additional 206 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Disc Medicine by 15,137.5% during the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock valued at $161,000 after purchasing an additional 2,422 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in Disc Medicine by 383.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock valued at $211,000 after purchasing an additional 3,152 shares during the last quarter. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Trading Up 0.5%

Disc Medicine stock opened at $60.04 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 21.94 and a current ratio of 21.94. The stock has a market cap of $2.27 billion, a PE ratio of -10.02 and a beta of 0.87. The stock has a 50-day moving average of $71.11 and a two-hundred day moving average of $75.84. Disc Medicine, Inc. has a one year low of $30.82 and a one year high of $99.50.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.69) by $0.07. The business had revenue of ($19.88) million for the quarter, compared to analysts’ expectations of $0.15 million. On average, research analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Insider Buying and Selling

In other Disc Medicine news, CEO John D. Quisel sold 13,264 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $833,775.04. Following the sale, the chief executive officer owned 226,064 shares of the company’s stock, valued at approximately $14,210,383.04. The trade was a 5.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jonathan Yen-Wen Yu sold 3,231 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $203,100.66. Following the transaction, the chief operating officer owned 54,324 shares in the company, valued at $3,414,806.64. The trade was a 5.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 124,199 shares of company stock worth $9,937,482 over the last ninety days. Company insiders own 3.64% of the company’s stock.

Analyst Upgrades and Downgrades

IRON has been the subject of a number of recent research reports. Wedbush reduced their target price on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a report on Tuesday, February 17th. TD Cowen restated a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th. UBS Group reaffirmed an “overweight” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Cantor Fitzgerald reduced their price objective on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a research note on Tuesday, February 17th. Finally, Morgan Stanley set a $75.00 target price on shares of Disc Medicine in a research report on Tuesday, February 17th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $104.80.

Disc Medicine Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.